Format

Send to

Choose Destination
Lancet Psychiatry. 2018 Dec;5(12):957-960. doi: 10.1016/S2215-0366(18)30303-1. Epub 2018 Nov 6.

Baclofen for the treatment of alcohol use disorder: the Cagliari Statement.

Author information

1
Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cittadella Universitaria, I-09042 Monserrato, Italy. Electronic address: agabio@unica.it.
2
Faculty of Medicine, University of Southampton, Southampton, UK.
3
AUD and Alcohol Related Diseases Unit, Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario A Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy; Department of Internal Medicine and Gastroenterology, Università Cattolica del Sacro Cuore, Rome, Italy.
4
Centre de Recherche en Epidémiologie et Santé des Populations, Faculté de Médecine, Université Paris-Sud, Paris, France; Faculté de Médecine, Université de Versailles Saint-Quentin-en-Yvelines, Paris, France; Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay, Paris, France; Hôpitaux Universitaires Paris-Sud, Paris, France.
5
Department of Psychology, University of Amsterdam, Amsterdam, Netherlands.
6
SS Annunziata Hospital, Department of Internal Medicine, Cento, Italy.
7
Castle Craig Hospital, Blyth Bridge, UK; School of Health and Social Care, Edinburgh Napier University, Edinburgh, UK.
8
Montpellier 34000, France.
9
Department of Addiction Médicine, Poisons and Substance Abuse Treatment Centre, Toulouse-Purpan University Hospital, Toulouse, France.
10
Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
11
National Health Medical Research Council, Centre of Research Excellence in Mental Health and Substance Use, Central Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
12
Department of Gastroenterology, Royal Alexandra Hospital Paisley, Paisley, UK.
13
Département de Médecine Générale, Faculté de Médecine, Université Paris Descartes, Paris, France.
14
Neuropsychopharmacology Unit, Centre for Psychiatry, Division of Brain Sciences, Imperial College London, London, UK.
15
Discipline of Addiction Medicine, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
16
Department of Psychiatry, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany.
17
Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK.
18
Department of Addiction Medicine, St Vincent's Hospital Melbourne, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.
19
Poison Control Centre, Toulouse-Purpan University Hospital, Toulouse, France.
20
Service Universitaire d'Addictologie de Lyon, Lyon, France; University of Lyon, Lyon, France.
21
Royal Perth Hospital, Perth, WA, Australia.
22
Department of Psychiatry, Amsterdam University Medical Centre, Academic Medical Centre, Amsterdam University, Amsterdam, Netherlands.
23
Groupe Hospitalier Paul-Guiraud, Paris, France.
24
Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism, Division of Intramural Clinical and Basic Research and National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Bethesda, MD, USA; Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA; Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, RI, USA.

Comment in

PMID:
30413394
DOI:
10.1016/S2215-0366(18)30303-1
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Spiral, Imperial College Digital Repository
Loading ...
Support Center